How Some COVID-19 Vaccines Could Cause Rare Blood Clots How Some COVID-19 Vaccines Could Cause Rare Blood Clots
Regulatory agencies in the US and around the world are scrambling to determine the risk of potentially lethal but rare blood clots linked to adenovirus vaccines.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2021 Category: Cardiology Tags: Infectious Diseases News Source Type: news
FDA and CDC Recommend Pausing COVID-19 Vaccination With J & J-Janssen Shot While They Investigate Blood Clot Risks
The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are recommending that vaccinations with the Johnson & Johnson/Janssen COVID-19 vaccine be temporarily halted while the agencies review reports of blood clots among vaccinated people.
On April 13, the two government agencies issued a joint statement announcing a recommended pause as federal regulators review six cases of blood clots reported six to 13 days after the people received the single-dose vaccine. “Until that [review] process is complete, we are recommending a pause in the use of this vaccine out of an abundance of cautio...
Source: TIME: Health - April 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot.
In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news
Science Saturday: Vaccine efforts move forward at Mayo Clinic
Humanity has taken on infectious agents, such as the virus that causes smallpox, and won. But cheer quietly. Smallpox eradication took 200 years, and it's just one of the many diseases out there. But hey, researchers are nothing if not persistent, right? A Mayo Clinic lab member is purifying an adenovirus vector for preclinical testing. That's [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 27, 2021 Category: Databases & Libraries Source Type: news
AstraZeneca ’s U.S. Study May Answer Some of the Lingering Questions About Its Vaccine
This study puts to bed any doubts that this isn’t a highly effective vaccine against COVID-19 disease and COVID-19 symptoms,” says Mene Pangalos, executive vice president for biopharmaceuticals research and development at AstraZeneca.
AstraZeneca’s vaccine is based on technology developed by scientists at Oxford University’s Jenner Institute, and involves using a chimpanzee adenovirus modified so it cannot cause the cold infection it normally does. The chimp virus acts as a vehicle to deliver genes into the body, where it encodes the SARS-CoV-2 spike protein; cells then process the protein so the im...
Source: TIME: Health - March 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Your coronavirus vaccine guide: Covishield vs Covaxin
Oxford-AstraZeneca made Covishield is based on the viral vector platform. The vaccine is made by genetically engineering adenovirus that normally infects chimpanzees. It uses double-stranded DNA. Bharat Biotech made Covaxin is based on an inactivated form of the coronavirus. (Source: The Economic Times)
Source: The Economic Times - March 2, 2021 Category: Consumer Health News Source Type: news
Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system.
The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test.
“Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said.
The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors.
This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA.
“Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising drug for this d...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Optimizing Adeno-Associated Virus (AAV) Manufacturing
Scientists wield nature ’s power to optimize adeno-associated virus (AAV) production and maximize gene therapy safety. (Source: The Scientist)
Source: The Scientist - February 16, 2021 Category: Science Tags: Research Products Blog Source Type: news
Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news
A new vision for adeno-associated virus delivered gene therapies
An international collaboration of leading groups in gene therapy and vision science have developed an adeno-associated virus (AAV) genome-coupled immunomodulation strategy that helps cloak the AAV virus from unwanted immune responses and offers important insights into ocular inflammation. The research led by Harvard University, Harvard Medical School and including the University of Bristol is published in Science Translational Medicine. (Source: University of Bristol news)
Source: University of Bristol news - February 11, 2021 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences, Faculty of Life Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news
Do Vaccines Stop the Spread of COVID-19? What You Need to Know
The way most people think of vaccines is pretty simple: you get vaccinated, and your immune system is primed and trained to fight off the invisible intruder in question, be it virus or bacteria. If you’re protected, you can’t be infected, and if you’re not infected, then you can’t spread it to anyone else.
And that’s true most of the time. But not all vaccines work that way, and it’s not actually what the two COVID-19 vaccines authorized by the U.S. Food and Drug Administration—made by Moderna and Pfizer-BioNtech—are designed to do. Their effectiveness is measured by how well...
Source: TIME: Health - February 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
High Efficacy Reported for Sputnik V COVID-19 Vaccine
THURSDAY, Feb. 4, 2021 -- A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), has 91.6 percent efficacy against COVID-19, according to a study published online Feb. 2 in The Lancet.
Denis Y. Logunov, D.Sc., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news
Intranasal influenza vaccine spurs strong immune response in Phase 1 study
(NIH/National Institute of Allergy and Infectious Diseases) An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in theJournal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 3, 2021 Category: Infectious Diseases Source Type: news
Lancet peer-reviewed study endorses Russia's Sputnik V Covid-19 vaccine
Sputnik V uses two adenoviruses, AD 5 and AD 26, that target the spike protein of the SARS Cov2 virus. Companies such as AstraZeneca, Johnson& Johnson and CanSino are using one of these 2 vectors for their vaccines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2021 Category: Pharmaceuticals Source Type: news
